Severe Mpox Among People With Advanced Human Immunodeficiency Virus Receiving Prolonged Tecovirimat in New York City

Open Forum Infect Dis. 2024 May 17;11(6):ofae294. doi: 10.1093/ofid/ofae294. eCollection 2024 Jun.

Abstract

Severe mpox has been observed in people with advanced human immunodeficiency virus (HIV). We describe clinical outcomes of 13 patients with advanced HIV (CD4 <200 cells/μL), severe mpox, and multiorgan involvement. Despite extended tecovirimat courses and additional agents, including vaccinia immune globulin, cidofovir, and brincidofovir, this group experienced prolonged hospitalizations and high mortality.

Keywords: HIV/AIDS; immunocompromise; mortality; mpox treatment; tecovirimat.